Next Article in Journal
Synthesis of N,N-Dimethylaminopropyl Derivative of A Blood Sugar Antigen
Previous Article in Journal
Benzyl 2-Phenyl-1H-pyrrole-1-carboxylate
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Short Note

tert-Butyl (6-(3-(3-Fluorophenyl)ureido)hexyl)carbamate

1
Department of Organic Chemistry, Volgograd State Technical University, Volgograd 400005, Russia
2
Laboratory of Metal Complex Catalysis, Kurnakov Institute of General and Inorganic Chemistry, Russian Academy of Sciences, Moscow 119991, Russia
*
Author to whom correspondence should be addressed.
Molbank 2025, 2025(2), M1984; https://doi.org/10.3390/M1984
Submission received: 6 March 2025 / Revised: 21 March 2025 / Accepted: 23 March 2025 / Published: 26 March 2025
(This article belongs to the Section Organic Synthesis and Biosynthesis)

Abstract

:
The title compound, tert-butyl (6-(3-(3-fluorophenyl)ureido)hexyl)carbamate, was synthesized and characterized by NMR, MS, elemental analysis, and single-crystal X-ray diffraction. This urea can serve as a framework for the preparation of unsymmetrical diureas or compounds containing both urea and thiourea groups.

1. Introduction

It is known that 1,3-disubstituted ureas are potent inhibitors of human soluble epoxide hydrolase (sEH) [1,2,3,4,5]. Such compounds are currently undergoing clinical (EC 5026, Figure 1) and preclinical (AMHDU, Figure 1) trials and may become a good alternative to opioid analgesics [6,7]. We have previously shown that symmetrical compounds containing two urea groups and two lipophilic fragments linked by an aliphatic spacer are capable of inhibiting soluble epoxide hydrolase in the picomolar concentration range [8]. However, from the point of view of synthetic chemistry, the described method is suitable for obtaining only symmetrical compounds, the properties of which are not always suitable for their use as drugs.
Therefore, the development of methods for the synthesis of unsymmetrical diureas and carbamates [9] is an urgent task. The present study is focused on the preparation and identification of tert-butyl (6-(3-(3-fluorophenyl)ureido)hexyl)carbamate, which can serve as a framework for the preparation of unsymmetrical diureas.

2. Results and Discussion

The idea was to use a Boc-protected diamine at one of its amino groups. Such a diamine is commercially available, but can also be easily prepared in the laboratory [10]. In our experience, dry ether is a good solvent for the synthesis of 1,3-disubstituted ureas, since the latter usually dissolve poorly in it. Compounds 1 and 2 dissolved well in ether, which determined our choice (Scheme 1). However, after 8 h of synthesis, despite the almost complete conversion of the initial compounds (according to TLC data), no urea precipitate was observed. Then, we added 1N HCl to the reaction mass and stirred the reaction mass until the ether was completely removed (about 1 h). During the evaporation of the ether, a precipitate of urea 3 was formed at the phase boundary.
The synthesis was repeated one more time with a similar yield. However, an unusual result was obtained in the third repetition. The synthesis was carried out by an undergraduate volunteer, who, due to attending classes, was unable to isolate the product after 8 h, and the reaction mass stood for two days. After this, precipitation in the form of large colorless crystals was discovered (Figure S3). The crystals were good enough for X-ray diffraction analysis without additional recrystallization. Apparently, over the extra 40 h, the ether took water from the atmosphere since the flask was not sealed, which led to the precipitation of urea. And since the process of ether saturation with water proceeded slowly, crystals of the correct shape grew.
The molecular structure of tert-butyl (6-(3-(3-fluorophenyl)ureido)hexyl)carbamate (3) was determined by single-crystal X-ray diffraction (SC XRD). According to the SC XRD data, 3 crystallizes in the monoclinic Pn space group with a unique complex molecule in an asymmetric unit. The molecule comprises four parts: a main six-membered carbon chain C(8)-C(13), a 3-fluorophenyl ring attached to N(1) (N,N′-disubstituted urea fragment), and a Boc-protecting group bonded to N(3) (Figure 2). All bond lengths and angles are within normal ranges (Tables S2 and S3 in the Supplementary Section). The general molecular conformation is a consequence of the twist of each terminal substituent to the main disubstituted aliphatic diamine. The dihedral angles between the mean plane of the 3-fluorophenyl group (atoms C(1)–C(6)) and the carboxylic group (atoms O(2)–C(14)–O(3)–C(15)) are 56.78(10)°. The orientation of the Boc-protecting group relative to the main chain gives a torsion angle of C(14)-N(3)-C(13)-C(12) = −118.7(2)°.
Crystal structure packing analysis revealed that molecules of 3 form layers and relatively strong intermolecular contacts due to the presence of hydrogen bonds N–H…O in the supramolecular structure, which can be classified as a classic type H-bonds based on the geometrical parameters (Table S4, Figure 3 and Figures S4 and S5). In the absence of stronger discoverable intermolecular interactions, these hydrogen bonds explain the molecular conformation and lead to the overall structure of the crystal.

3. Materials and Methods

The 1H and 13C NMR spectra were taken with a Bruker DPX 300 machine (Bruker AXS GmbH, Karlsruhe, Germany) at a frequency of 300 and 75 MHz in DMSO-d6 solution with TMS as the standard. The J values are given in Hz. The MS spectrum was measured on a Finnigan MAT INCOSTM 50 (Thermo Fisher Scientific, Waltham, MA, USA) using electron impact ionization (EI). The elemental analysis was performed on a Perkin-Elmer Series II 2400 Elemental Analyzer (Perkin Elmer Inc., Waltham, MA, USA). The TLC analysis was carried out on Merck silica gel chromatography plates with the fluorescent indicator F254 (1.05554); the sorbent Silica 60; a layer thickness of 200 µm; a pore size of 60 Å; a particle size of 10–12 µm; and organic polymer as a binder (Merck KGaA, Darmstadt, Germany). The melting points were measured on a Büchi M-565 (Büchi Labortechnik AG, Flawil, Switzerland), and the average values of three independent experiments were recorded. The solvents and reagents were purchased from commercial sources.

3.1. X-Ray Crystallography

The single-crystal X-ray data for 3 were collected using a Bruker D8 Venture Photon II four-circle diffractometer (Bruker, Billerica, MA, USA) in ω-scan mode (Cu Kα radiation, λ = 1.54178 Å) at the Center for Collective Use of the Kurnakov Institute RAS (Moscow, Russia). The raw data were indexed and integrated with the APEX3 program suite (Bruker AXS Inc., Madison, WI, USA, 2016). The experimental intensities were corrected for absorption effects using SADABS [11]. The crystal structure was solved using direct methods [12] and refined via full-matrix least-squares on F2 [13] using the OLEX2 structural data visualization and analysis program suite [14]. All non-hydrogen atoms were refined with anisotropic thermal parameters. The C–H hydrogen atoms were placed in the calculated positions and refined using a riding model with dependent isotropic thermal parameters, with Uiso(H) = 1.5Ueq(C) for the methyl groups and with Uiso(H) = 1.2Ueq(C) for other hydrogen atoms, while N–H hydrogen atoms were located in difference-Fourier maps and refined independently. The crystallographic data and structure refinement details for 3 are given in Table S1. CCDC entry 2,426,014 contains the supplementary crystallographic data for this paper. These data are provided free of charge by the Cambridge Crystallographic Data Centre: ccdc.cam.ac.uk/structures (accessed on 21 February 2025). The corresponding CIF files are also available as Supporting Information.
Crystal data for 3: C18H28FN3O3, M = 353.43, Pn, a = 5.07017(8) Å, b = 22.1104(4) Å, c = 8.60307(14) Å, β = 102.0417(7)°, V = 943.21(3) Å3, Z = 2, dcalc = 1.244 g/cm3. A colorless single-crystal prism with dimensions of 0.20 × 0.12 × 0.08 mm was selected, and the intensities of 14,672 reflections were collected (μ = 0.756 mm−1, θmax = 74.515°). After the merging of equivalence reflections and absorption corrections, 3691 independent reflections (Rint = 0.0355) were used for the structure solution and refinement. The final R factor R1 was 0.0328 [for 3594 reflections with F2 > 2σ(F2)], wR2 was 0.0884 (for all reflections), S was 1.093, and the largest diff. peak and hole were 0.219 and −0.213 e/Å3, respectively.

3.2. Synthesis of tert-Butyl (6-(3-(3-Fluorophenyl)ureido)hexyl)carbamate (3)

Into a flat-bottom flask equipped with magnetic stirrer were added 1130 mg (5.23 mmol) of tert-butyl (6-aminohexyl)carbamate (1), 16 mL of anhydrous Et2O, 700 mg (5.11 mmol) of 3-fluorophenyl isocyanate = (2), and 730 mg (7.22 mmol, 1 mL) of Et3N. The resulting mixture was left to be stirred for 8 h at rt. Then, 15 mL of 1 N HCl was added, followed by the formation of white precipitate. After stirring for another 1 h, the precipitate was filtered off, washed with 30 mL of distilled water and dried in vacuo. The resulting crude tert-butyl (6-(3-(3-fluorophenyl)ureido)hexyl)carbamate (3) was purified by crystallization from ethanol. Alternatively, the reaction mass could be left for 48 h to acquire colorless crystals of 3 suitable for X-Ray diffraction analysis. Pure tert-butyl (6-(3-(3-fluorophenyl)ureido)hexyl)carbamate (3): 1050 mg, 2.97 mmol, 58% yield (for both methods), white solid. Mp = 99.2 °C. Mass spectrum, m/z (Irel. %): 353 (1.5% [M]+), 252 (18%), 137 (30% [OCN-Ph-F]+), 111 (100% [H2N-Ph-Fl]+). 1H NMR (CDCl3), δ, ppm: 1.23–1.29 (m, 4H, 2CH2), 1.35–1.43 (m, 13H, 2CH2, 3CH3), 2.91 (q, 2H, J = 6.5 Hz, CH2-NH-C(O)NH), 3.07 (q, 2H, J = 6.7 Hz, CH2-NH-C(O)O), 6.18 (t, 1H, J = 5.7 Hz, NH-CH2), 6.66 (tdd, 1H, J = 8.5, 2.6, 0.9 Hz, 4-H Ph), 6.72 (br.t, 1H, NH-C(O)O), 7.01 (ddd, 1H, J = 8.2, 2.0, 0.9 Hz, 6-H Ph), 7.21 (td, 1H, J = 8.2, 6.9 Hz, 5-H Ph), 7.45 (dt, 1H, J = 12.3, 2.3 Hz, 2-H Ph), 8.61 (s, 1H, NH-Ph). 13C NMR (CDCl3), δ, ppm: 26.5 (2C, 2CH2), 28.7 (3C, 3CH3), 29.9 (1C, CH2), 30.1 (1C, CH2), 39.4 (1C, CH2-NH-C(O)O), 40.3 (1C, CH2-NH-CO-NH), 77.7 (1C, C(CH3)3), 104.7 (d, 1C, J = 26.6 Hz, 4-C Ph), 107.5 (d, 1C, J = 21.2 Hz, 2-C Ph), 113.7 (1C, 6-C Ph), 130.5 (d, 1C, J = 9.7 Hz, 5-C Ph), 143.0 (d, 1C, J = 11.4 Hz, 1-C Ph), 155.4 (1C, NH-CO-NH), 156.0 (1C, NH-C(O)O), 162.9 (d, 1C, J = 240.1 Hz, C-F). Calc. for C18H28FN3O3: C 61.17; H 7.99; N 11.89. Found: 61.20; H 8.00.; N 11.85. M = 353.44.

4. Conclusions

In this work, we described the preparation of a new compound, tert-butyl (6-(3-(3-fluorophenyl)ureido)hexyl)carbamate, and identified it with 1H and 13C NMR, MS, and single-crystal X-ray diffraction.

Supplementary Materials

Figure S1. 1H NMR spectrum of compound 3. Figure S2. 13C NMR spectrum of compound 3. Figure S3. Precipitate of compound 3. Figure S4. Hydrogen bonding between molecules of compound 3. Figure S5. Hydrogen bonding between molecules of compound 3. Table S1. Crystal data and structure refinement for 3. Table S2. Selected bond lengths for 3. Table S3. Selected angles for 3. Table S4. Hydrogen bonds for 3 [Å and angles].

Author Contributions

Conceptualization, D.Z.; investigation, D.Z., K.E., J.B., I.A.Y. and A.M.; writing, review, and editing, I.A.Y. and V.B.; project administration, V.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research was conducted with the support of the VSTU development program “Priority 2030”, within the framework of scientific project number 13/651-24.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data are available within the article or its Supplementary Materials.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Luo, A.; Wu, Z.; Li, S.; McReynolds, C.B.; Wang, D.; Liu, H.; Huang, C.; He, T.; Zhang, X.; Wang, Y.; et al. The soluble epoxide hydrolase inhibitor TPPU improves comorbidity of chronic pain and depression via the AHR and TSPO signaling. J. Transl. Med. 2023, 21, 71. [Google Scholar] [CrossRef] [PubMed]
  2. Codony, S.; Entrena, J.M.; Calvó-Tusell, C.; Jora, B.; González-Cano, R.; Osuna, S.; Corpas, R.; Morisseau, C.; Pérez, B.; Barniol-Xicota, M.; et al. Synthesis, In Vitro Profiling, and In Vivo Evaluation of Benzohomoadamantane-Based Ureas for Visceral Pain: A New Indication for Soluble Epoxide Hydrolase Inhibitors. J. Med. Chem. 2022, 65, 13660–13680. [Google Scholar] [CrossRef] [PubMed]
  3. Wang, Y.; Wagner, K.M.; Morisseau, C.; Hammock, B.D. Inhibition of the Soluble Epoxide Hydrolase as an An-algesic Strategy: A Review of Preclinical Evidence. J. Pain Res. 2021, 14, 61–72. [Google Scholar] [CrossRef] [PubMed]
  4. Sun, C.-P.; Zhang, X.-Y.; Morisseau, C.; Hwang, S.H.; Zhang, Z.-J.; Hammock, B.D.; Ma, X.-C. Discovery of Soluble Epoxide Hydrolase Inhibitors from Chemical Synthesis and Natural Products. J. Med. Chem. 2021, 64, 184–215. [Google Scholar] [CrossRef] [PubMed]
  5. McReynolds, C.B.; Yang, J.; Guedes, A.; Morisseau, C.; Garcia, R.; Knych, H.; Tearney, C.; Hamamoto, B.; Hwang, S.H.; Wagner, K.; et al. Species Differences in Metabolism of Soluble Epoxide Hydrolase Inhibitor, EC1728, Highlight the Importance of Clinically Relevant Screening Mechanisms in Drug Development. Molecules 2021, 26, 5034. [Google Scholar] [CrossRef] [PubMed]
  6. Hammock, B.D.; McReynolds, C.B.; Wagner, K.; Buckpitt, A.; Cortes-Puch, I.; Croston, G.; Lee, K.S.S.; Yang, J.; Schmidt, W.K.; Hwang, S.H. Movement to the Clinic of Soluble Epoxide Hydrolase Inhibitor EC5026 as an Analgesic for Neuropathic Pain and for Use as a Nonaddictive Opioid Alternative. J. Med. Chem. 2021, 64, 1856–1872. [Google Scholar] [CrossRef] [PubMed]
  7. Babkov, D.; Eliseeva, N.; Adzhienko, K.; Bagmetova, V.; Danilov, D.; McReynolds, C.B.; Morisseau, C.; Hammock, B.D.; Burmistrov, V. Preclinical Evaluation of Soluble Epoxide Hydrolase Inhibitor AMHDU against Neuropathic Pain. Int. J. Mol. Sci. 2024, 25, 8841. [Google Scholar] [CrossRef] [PubMed]
  8. Burmistrov, V.V.; Morisseau, C.; Danilov, D.V.; Gladkikh, B.P.; D’yachenko, V.S.; Zefirov, N.A.; Zefirova, O.N.; Butov, G.M.; Hammock, B.D. Fluorine and chlorine substituted adamantyl-urea as molecular tools for inhibition of human soluble epoxide hydrolase with picomolar efficacy. J. Enzym. Inhib. Med. Chem. 2023, 38, 2274797. [Google Scholar] [CrossRef] [PubMed]
  9. Li, Y.X.; Qiu, Z. Concise Syntheses and Antitumor Activities of A-Hydroxy(Mercapto)Amide Derivatives. Asian J. Chem. 2014, 26, 3219–3223. [Google Scholar] [CrossRef]
  10. Howell, L.A.; Gulam, R.; Mueller, A.; O’Connell, M.A.; Searcey, M. Design and Synthesis of Threading Intercalators to Target DNA. Bioorg. Med. Chem. Lett. 2010, 20, 6956–6959. [Google Scholar] [CrossRef] [PubMed]
  11. Krause, L.; Herbst-Irmer, R.; Sheldrick, G.M.; Stalke, D. Comparison of Silver and Molybdenum Microfocus X-Ray Sources for Single-Crystal Structure Determination. J. Appl. Crystallogr. 2015, 48, 3–10. [Google Scholar] [CrossRef] [PubMed]
  12. Sheldrick, G.M. SHELXT—Integrated Space-Group and Crystal-Structure Determination. Acta Crystallographica. Sect. A Found. Adv. 2015, 71, 3–8. [Google Scholar] [CrossRef] [PubMed]
  13. Sheldrick, G.M. Crystal Structure Refinement with SHELXL. Acta Crystallographica. Sect. C Struct. Chem. 2015, 71, 3–8. [Google Scholar] [CrossRef] [PubMed]
  14. Dolomanov, O.V.; Bourhis, L.J.; Gildea, R.J.; Howard, J.A.K.; Puschmann, H. OLEX2: A Complete Structure Solution, Refinement and Analysis Program. J. Appl. Crystallogr. 2009, 42, 339–341. [Google Scholar] [CrossRef]
Figure 1. Chemical structures of late-stage sEH inhibitors.
Figure 1. Chemical structures of late-stage sEH inhibitors.
Molbank 2025 m1984 g001
Scheme 1. Synthesis of tert-butyl (6-(3-(3-fluorophenyl)ureido)hexyl)carbamate (3) from tert-butyl (6-aminohexyl)carbamate (1) and 3-fluorophenyl isocyanate (2).
Scheme 1. Synthesis of tert-butyl (6-(3-(3-fluorophenyl)ureido)hexyl)carbamate (3) from tert-butyl (6-aminohexyl)carbamate (1) and 3-fluorophenyl isocyanate (2).
Molbank 2025 m1984 sch001
Figure 2. The molecular structure and atom numbering scheme of tert-butyl (6-(3-(3-fluorophenyl)ureido)hexyl)carbamate (3), with displacement ellipsoids drawn at the 50% probability level.
Figure 2. The molecular structure and atom numbering scheme of tert-butyl (6-(3-(3-fluorophenyl)ureido)hexyl)carbamate (3), with displacement ellipsoids drawn at the 50% probability level.
Molbank 2025 m1984 g002
Figure 3. Fragment of crystal packing of tert-butyl (6-(3-(3-fluorophenyl)ureido)hexyl)carbamate (3). View along crystallographic axis a.
Figure 3. Fragment of crystal packing of tert-butyl (6-(3-(3-fluorophenyl)ureido)hexyl)carbamate (3). View along crystallographic axis a.
Molbank 2025 m1984 g003
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Zapravdina, D.; Eremeev, K.; Yakushev, I.A.; Maksimova, A.; Bynerie, J.; Burmistrov, V. tert-Butyl (6-(3-(3-Fluorophenyl)ureido)hexyl)carbamate. Molbank 2025, 2025, M1984. https://doi.org/10.3390/M1984

AMA Style

Zapravdina D, Eremeev K, Yakushev IA, Maksimova A, Bynerie J, Burmistrov V. tert-Butyl (6-(3-(3-Fluorophenyl)ureido)hexyl)carbamate. Molbank. 2025; 2025(2):M1984. https://doi.org/10.3390/M1984

Chicago/Turabian Style

Zapravdina, Daria, Konstantin Eremeev, Ilya A. Yakushev, Anna Maksimova, Jourdan Bynerie, and Vladimir Burmistrov. 2025. "tert-Butyl (6-(3-(3-Fluorophenyl)ureido)hexyl)carbamate" Molbank 2025, no. 2: M1984. https://doi.org/10.3390/M1984

APA Style

Zapravdina, D., Eremeev, K., Yakushev, I. A., Maksimova, A., Bynerie, J., & Burmistrov, V. (2025). tert-Butyl (6-(3-(3-Fluorophenyl)ureido)hexyl)carbamate. Molbank, 2025(2), M1984. https://doi.org/10.3390/M1984

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop